Donald James Annino, Jr., D.M.D., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 24 | 2023 | 2712 | 1.600 |
Why?
|
| Neck Dissection | 7 | 2011 | 196 | 1.090 |
Why?
|
| Facial Transplantation | 5 | 2021 | 226 | 1.050 |
Why?
|
| Carcinoma, Squamous Cell | 18 | 2024 | 4029 | 0.930 |
Why?
|
| Osteoradionecrosis | 1 | 2022 | 49 | 0.860 |
Why?
|
| Esophageal Stenosis | 4 | 2013 | 194 | 0.650 |
Why?
|
| Free Tissue Flaps | 1 | 2022 | 320 | 0.640 |
Why?
|
| Radiotherapy, Intensity-Modulated | 8 | 2022 | 806 | 0.620 |
Why?
|
| Paranasal Sinuses | 1 | 2020 | 249 | 0.610 |
Why?
|
| Endoscopy | 4 | 2020 | 1774 | 0.600 |
Why?
|
| Enophthalmos | 2 | 2008 | 34 | 0.580 |
Why?
|
| Maxillary Sinusitis | 2 | 2008 | 39 | 0.570 |
Why?
|
| Rhinoplasty | 1 | 2020 | 226 | 0.570 |
Why?
|
| Maxillary Sinus | 2 | 2008 | 180 | 0.520 |
Why?
|
| Orbital Diseases | 2 | 2008 | 181 | 0.490 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2022 | 1009 | 0.490 |
Why?
|
| Dilatation | 3 | 2013 | 286 | 0.480 |
Why?
|
| Neoplasms, Unknown Primary | 3 | 2022 | 104 | 0.440 |
Why?
|
| Mouth Neoplasms | 4 | 2024 | 601 | 0.410 |
Why?
|
| Deglutition Disorders | 4 | 2011 | 604 | 0.360 |
Why?
|
| Salivary Gland Neoplasms | 2 | 2020 | 297 | 0.330 |
Why?
|
| Paranasal Sinus Diseases | 1 | 2008 | 116 | 0.290 |
Why?
|
| Radiation Injuries | 2 | 2019 | 1178 | 0.290 |
Why?
|
| Relative Biological Effectiveness | 1 | 2008 | 323 | 0.280 |
Why?
|
| Oropharyngeal Neoplasms | 3 | 2022 | 475 | 0.270 |
Why?
|
| Radiotherapy, Conformal | 1 | 2008 | 548 | 0.250 |
Why?
|
| Facial Neuralgia | 1 | 2003 | 10 | 0.240 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2005 | 138 | 0.240 |
Why?
|
| Laryngectomy | 2 | 2003 | 248 | 0.240 |
Why?
|
| Toothache | 1 | 2003 | 34 | 0.230 |
Why?
|
| Pharyngectomy | 1 | 2003 | 45 | 0.230 |
Why?
|
| Lipectomy | 1 | 2005 | 118 | 0.230 |
Why?
|
| Facial Injuries | 3 | 2014 | 183 | 0.230 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2003 | 112 | 0.230 |
Why?
|
| Larynx | 1 | 2008 | 492 | 0.230 |
Why?
|
| Ultrasonic Therapy | 1 | 2005 | 235 | 0.220 |
Why?
|
| Mitomycin | 1 | 2003 | 259 | 0.220 |
Why?
|
| HIV Protease Inhibitors | 1 | 2005 | 430 | 0.220 |
Why?
|
| Pharyngeal Diseases | 1 | 2003 | 132 | 0.210 |
Why?
|
| Radiotherapy, Adjuvant | 6 | 2011 | 1769 | 0.200 |
Why?
|
| Nasolacrimal Duct | 1 | 2022 | 74 | 0.200 |
Why?
|
| Face | 2 | 2020 | 993 | 0.200 |
Why?
|
| Neoadjuvant Therapy | 4 | 2023 | 2721 | 0.190 |
Why?
|
| Papillomavirus Infections | 2 | 2022 | 1585 | 0.190 |
Why?
|
| Graft Rejection | 4 | 2021 | 4393 | 0.180 |
Why?
|
| Combined Modality Therapy | 13 | 2013 | 8621 | 0.180 |
Why?
|
| Nasal Mucosa | 2 | 2020 | 373 | 0.180 |
Why?
|
| Middle Aged | 38 | 2024 | 213127 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2021 | 9185 | 0.170 |
Why?
|
| Skin Pigmentation | 1 | 2021 | 281 | 0.170 |
Why?
|
| Radiotherapy Dosage | 6 | 2022 | 2876 | 0.160 |
Why?
|
| Mouth Mucosa | 1 | 2020 | 434 | 0.150 |
Why?
|
| Microsurgery | 1 | 2003 | 796 | 0.150 |
Why?
|
| Retrospective Studies | 21 | 2022 | 77098 | 0.150 |
Why?
|
| Male | 46 | 2024 | 349538 | 0.150 |
Why?
|
| Esophagoscopy | 2 | 2013 | 390 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2014 | 20086 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2011 | 3471 | 0.150 |
Why?
|
| Postoperative Complications | 5 | 2021 | 15244 | 0.150 |
Why?
|
| Precancerous Conditions | 1 | 2024 | 971 | 0.140 |
Why?
|
| Transplantation, Homologous | 3 | 2021 | 4771 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2021 | 11472 | 0.140 |
Why?
|
| Surgical Flaps | 2 | 2003 | 1634 | 0.130 |
Why?
|
| Aged | 29 | 2021 | 162944 | 0.130 |
Why?
|
| Treatment Outcome | 17 | 2021 | 62966 | 0.130 |
Why?
|
| Female | 38 | 2024 | 379592 | 0.130 |
Why?
|
| Ear, External | 1 | 1995 | 160 | 0.130 |
Why?
|
| Zenker Diverticulum | 1 | 2014 | 20 | 0.120 |
Why?
|
| Humans | 56 | 2024 | 742088 | 0.120 |
Why?
|
| Adult | 26 | 2023 | 213712 | 0.120 |
Why?
|
| Reoperation | 2 | 2021 | 4200 | 0.120 |
Why?
|
| Epistaxis | 1 | 2014 | 111 | 0.120 |
Why?
|
| Surgical Stapling | 1 | 2014 | 97 | 0.120 |
Why?
|
| Sphenoid Bone | 1 | 2014 | 172 | 0.110 |
Why?
|
| Solitary Fibrous Tumor, Pleural | 1 | 2013 | 25 | 0.110 |
Why?
|
| Lymph Nodes | 1 | 2005 | 3465 | 0.110 |
Why?
|
| Paranasal Sinus Neoplasms | 2 | 2007 | 234 | 0.110 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 890 | 0.100 |
Why?
|
| Laryngeal Neoplasms | 3 | 2011 | 512 | 0.100 |
Why?
|
| Orbital Neoplasms | 1 | 2013 | 225 | 0.090 |
Why?
|
| Neck | 2 | 2005 | 693 | 0.090 |
Why?
|
| Vincristine | 1 | 1992 | 1036 | 0.090 |
Why?
|
| Syndrome | 2 | 2008 | 3248 | 0.090 |
Why?
|
| Aged, 80 and over | 12 | 2021 | 57683 | 0.090 |
Why?
|
| Deglutition | 1 | 2011 | 197 | 0.090 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2023 | 3014 | 0.090 |
Why?
|
| Airway Obstruction | 1 | 2014 | 663 | 0.090 |
Why?
|
| Risk Assessment | 3 | 2019 | 23320 | 0.090 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2009 | 96 | 0.090 |
Why?
|
| Vocal Cord Paralysis | 1 | 1992 | 267 | 0.080 |
Why?
|
| Recovery of Function | 3 | 2014 | 2924 | 0.080 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 1683 | 0.080 |
Why?
|
| Pleural Neoplasms | 1 | 2013 | 607 | 0.080 |
Why?
|
| Lymphatic Metastasis | 3 | 2010 | 2906 | 0.080 |
Why?
|
| Cancer Care Facilities | 3 | 2019 | 401 | 0.070 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2008 | 876 | 0.070 |
Why?
|
| Otorhinolaryngologic Neoplasms | 1 | 2006 | 25 | 0.070 |
Why?
|
| Antineoplastic Agents | 4 | 2023 | 13655 | 0.070 |
Why?
|
| Hospitalization | 2 | 2020 | 10232 | 0.070 |
Why?
|
| Models, Economic | 1 | 2009 | 713 | 0.060 |
Why?
|
| Matrix Metalloproteinases | 1 | 2007 | 391 | 0.060 |
Why?
|
| Respiration Disorders | 1 | 2008 | 370 | 0.060 |
Why?
|
| Diplopia | 1 | 2005 | 199 | 0.060 |
Why?
|
| Disease-Free Survival | 3 | 2021 | 6891 | 0.060 |
Why?
|
| Survival Analysis | 5 | 2019 | 10248 | 0.060 |
Why?
|
| Leukoplakia, Oral | 1 | 2024 | 73 | 0.060 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2003 | 117 | 0.060 |
Why?
|
| Neoplasm Staging | 4 | 2010 | 11001 | 0.060 |
Why?
|
| Neurosurgical Procedures | 1 | 2014 | 2002 | 0.060 |
Why?
|
| Organ Specificity | 1 | 2008 | 2003 | 0.060 |
Why?
|
| Eating | 1 | 2010 | 1535 | 0.050 |
Why?
|
| Neoplasms, Second Primary | 1 | 2010 | 1052 | 0.050 |
Why?
|
| Frontal Sinus | 1 | 2002 | 50 | 0.050 |
Why?
|
| Orbit | 1 | 2005 | 427 | 0.050 |
Why?
|
| Dermoid Cyst | 1 | 2002 | 92 | 0.050 |
Why?
|
| Administration, Topical | 1 | 2003 | 688 | 0.050 |
Why?
|
| Tumor Microenvironment | 2 | 2024 | 3564 | 0.050 |
Why?
|
| Parotid Gland | 1 | 2022 | 168 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 12344 | 0.050 |
Why?
|
| Survival Rate | 3 | 2010 | 12773 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2010 | 6452 | 0.050 |
Why?
|
| Nose Neoplasms | 1 | 2002 | 245 | 0.050 |
Why?
|
| Organs at Risk | 1 | 2022 | 346 | 0.040 |
Why?
|
| Constriction, Pathologic | 1 | 2003 | 1095 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2005 | 9144 | 0.040 |
Why?
|
| Skull Base Neoplasms | 1 | 2002 | 284 | 0.040 |
Why?
|
| Range of Motion, Articular | 1 | 2005 | 1577 | 0.040 |
Why?
|
| Patient Selection | 1 | 2010 | 4214 | 0.040 |
Why?
|
| Radiation Dosage | 2 | 2022 | 1927 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2023 | 4438 | 0.040 |
Why?
|
| Cohort Studies | 4 | 2020 | 40450 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 2 | 2009 | 891 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 11039 | 0.040 |
Why?
|
| Kidney Neoplasms | 1 | 2013 | 4229 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2016 | 53 | 0.030 |
Why?
|
| Papillomaviridae | 1 | 2022 | 1118 | 0.030 |
Why?
|
| Mucous Membrane | 1 | 2019 | 670 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2023 | 2680 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2021 | 1269 | 0.030 |
Why?
|
| Ear Canal | 1 | 1995 | 146 | 0.030 |
Why?
|
| Length of Stay | 2 | 2021 | 6294 | 0.030 |
Why?
|
| Embryonic and Fetal Development | 1 | 1995 | 438 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 15056 | 0.030 |
Why?
|
| Laryngismus | 1 | 1994 | 28 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2016 | 462 | 0.030 |
Why?
|
| Vocal Cords | 2 | 2000 | 528 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2009 | 6259 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2019 | 6534 | 0.030 |
Why?
|
| Thermosensing | 1 | 2013 | 56 | 0.030 |
Why?
|
| Esophageal Neoplasms | 1 | 2003 | 1581 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2022 | 1622 | 0.030 |
Why?
|
| Laryngeal Muscles | 1 | 1994 | 98 | 0.030 |
Why?
|
| Acute Disease | 1 | 2003 | 7141 | 0.030 |
Why?
|
| Prognosis | 3 | 2008 | 29010 | 0.030 |
Why?
|
| Follow-Up Studies | 5 | 2013 | 39004 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2021 | 8297 | 0.030 |
Why?
|
| Receptor, Notch1 | 1 | 2016 | 502 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 704 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 20774 | 0.030 |
Why?
|
| Nasal Cavity | 1 | 2014 | 312 | 0.030 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2005 | 1808 | 0.030 |
Why?
|
| Botulinum Toxins | 1 | 1994 | 192 | 0.030 |
Why?
|
| Respiratory Sounds | 2 | 1994 | 693 | 0.030 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2011 | 50 | 0.030 |
Why?
|
| Hemostasis | 1 | 2014 | 458 | 0.030 |
Why?
|
| Aneurysm, False | 1 | 2014 | 276 | 0.030 |
Why?
|
| Androgen Antagonists | 1 | 2020 | 1350 | 0.020 |
Why?
|
| Touch | 1 | 2013 | 306 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2013 | 657 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2011 | 15530 | 0.020 |
Why?
|
| Xerostomia | 1 | 2010 | 95 | 0.020 |
Why?
|
| Voice Disorders | 1 | 1994 | 276 | 0.020 |
Why?
|
| Health Personnel | 1 | 2023 | 3210 | 0.020 |
Why?
|
| Receptor, erbB-2 | 1 | 2020 | 2410 | 0.020 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2013 | 349 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2006 | 5133 | 0.020 |
Why?
|
| Quality of Life | 3 | 2021 | 12730 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2018 | 2133 | 0.020 |
Why?
|
| Melanoma | 1 | 2007 | 5462 | 0.020 |
Why?
|
| Gastrostomy | 1 | 2011 | 309 | 0.020 |
Why?
|
| Retreatment | 1 | 2010 | 604 | 0.020 |
Why?
|
| Cerebral Angiography | 1 | 2014 | 1285 | 0.020 |
Why?
|
| DNA | 1 | 2022 | 7289 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2021 | 3300 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2013 | 1849 | 0.020 |
Why?
|
| Surgical Wound Infection | 2 | 2011 | 1538 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2024 | 4414 | 0.020 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2007 | 61 | 0.020 |
Why?
|
| Boston | 2 | 2011 | 9305 | 0.020 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2007 | 103 | 0.020 |
Why?
|
| Respiration | 1 | 1994 | 1645 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2009 | 10943 | 0.020 |
Why?
|
| Laryngoscopy | 1 | 1992 | 706 | 0.020 |
Why?
|
| Erythrocyte Transfusion | 1 | 2011 | 565 | 0.020 |
Why?
|
| Carboplatin | 1 | 2009 | 799 | 0.020 |
Why?
|
| Markov Chains | 1 | 2009 | 969 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 1434 | 0.020 |
Why?
|
| Taxoids | 1 | 2009 | 665 | 0.020 |
Why?
|
| Risk Factors | 2 | 2014 | 72145 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2003 | 6347 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2007 | 472 | 0.020 |
Why?
|
| Young Adult | 3 | 2017 | 56350 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2016 | 2948 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2009 | 1615 | 0.020 |
Why?
|
| Embolization, Therapeutic | 1 | 2014 | 1392 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2007 | 638 | 0.020 |
Why?
|
| Base Sequence | 1 | 2016 | 12797 | 0.020 |
Why?
|
| Adenoma | 1 | 2014 | 2168 | 0.010 |
Why?
|
| Quality Improvement | 1 | 2019 | 3738 | 0.010 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 3585 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 3691 | 0.010 |
Why?
|
| Cisplatin | 1 | 2009 | 1637 | 0.010 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2009 | 1679 | 0.010 |
Why?
|
| Cerebrospinal Fluid Otorrhea | 1 | 2002 | 15 | 0.010 |
Why?
|
| Cranial Nerve Injuries | 1 | 2002 | 25 | 0.010 |
Why?
|
| Diet | 2 | 2014 | 7923 | 0.010 |
Why?
|
| Incidence | 2 | 2014 | 20928 | 0.010 |
Why?
|
| Recurrence | 1 | 2014 | 8333 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 2 | 2009 | 9274 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2009 | 1707 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 8425 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 2008 | 921 | 0.010 |
Why?
|
| Cerebrospinal Fluid Rhinorrhea | 1 | 2002 | 80 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 24913 | 0.010 |
Why?
|
| Adolescent | 2 | 2023 | 85649 | 0.010 |
Why?
|
| Age of Onset | 1 | 2007 | 3266 | 0.010 |
Why?
|
| Endovascular Procedures | 1 | 2014 | 1973 | 0.010 |
Why?
|
| Travel | 1 | 2006 | 788 | 0.010 |
Why?
|
| Meningitis | 1 | 2002 | 216 | 0.010 |
Why?
|
| Dura Mater | 1 | 2002 | 291 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2020 | 53187 | 0.010 |
Why?
|
| Thyroid Cartilage | 1 | 2000 | 42 | 0.010 |
Why?
|
| Surgical Mesh | 1 | 2002 | 256 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 9410 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2014 | 4595 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2009 | 2680 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2016 | 9639 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2013 | 4933 | 0.010 |
Why?
|
| Craniotomy | 1 | 2002 | 729 | 0.010 |
Why?
|
| Bone Transplantation | 1 | 2002 | 907 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2009 | 5385 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2006 | 2049 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2009 | 6191 | 0.010 |
Why?
|
| Prostheses and Implants | 1 | 2002 | 1385 | 0.010 |
Why?
|
| Gene Expression | 1 | 2007 | 7790 | 0.010 |
Why?
|
| Hypertension | 1 | 2014 | 8455 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 14720 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 11363 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 8829 | 0.010 |
Why?
|
| Disease Progression | 1 | 2009 | 13256 | 0.010 |
Why?
|
| Laser Therapy | 1 | 2000 | 1071 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2013 | 35342 | 0.010 |
Why?
|
| Radiography | 1 | 2002 | 7010 | 0.010 |
Why?
|
| Infant | 1 | 1992 | 35070 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2007 | 8925 | 0.010 |
Why?
|
| Child, Preschool | 1 | 1992 | 40955 | 0.010 |
Why?
|
| Time Factors | 1 | 1994 | 40054 | 0.000 |
Why?
|